IRulya Therapeutics Inc. officer Dirk Thye gave notice of a proposed sale of 3,700 common shares, with an aggregate market value of $133,328.85. The notice lists an approximate sale date of October 21, 2026, and names Merrill as broker and NASDAQ as the exchange.
IRulya Therapeutics Inc. (IRLA) reports that Chief Operating Officer Keith R. Fandrick directly holds employee stock options covering common shares. Listed option records include exercise prices of $1.80, $1.81, $1.84 and $16.81, with expiration dates from July 24, 2027, through May 11, 2036. Some options are immediately exercisable; others vest in 36 successive equal monthly installments subject to continued service. The footnotes state that multiple options were received in exchange for Orphai options under the merger agreement.
IRulya Therapeutics Inc. posted its October 2026 corporate presentation, describing LAM-001, a once-daily inhaled rapamycin candidate, across Phase 2 programs for pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome (BOS), and sarcoidosis-associated pulmonary hypertension (SAPH).
In an open-label Phase 2a study of 10 patients, the 24-week mean change in 6-minute walk distance was +81.3 m in the evaluable population (N=6) and +67.4 m in the PH-ILD subgroup (N=4). Exercise pulmonary vascular resistance changed -25.5% and -35.3%, respectively.
PH-ILD Phase 2b data are anticipated in 1Q 2028, BOS Phase 2 data in 1Q 2027, and SAPH Phase 2 data in 4Q 2028; SAPH trial initiation is anticipated in 4Q 2026. In the ongoing blinded BOS study, an interim review in February 2026 found that five of 19 subjects had an FEV1 decline greater than 10%. The study remained blinded, and the interim results were described as preliminary and not indicative of final results; dosing continues.
Quince Therapeutics, Inc. (QNCX) is the issuer in a Schedule 13G reporting beneficial ownership attributed to Foresite Capital Fund VI LP, Foresite Public & Crossover Opportunities Fund I, L.P., their respective management entities, and James B. Tananbaum. Tananbaum reported beneficial ownership of 652,039 shares, or 6.0%, comprising 489,029 shares held by Foresite Capital Fund VI LP and 163,010 held by Foresite Public & Crossover Opportunities Fund I, L.P. The shares are Series C Preferred Stock on an as-converted basis.
The two funds reported 489,029 shares (4.5%) and 163,010 shares (1.5%), respectively. Their general partners and Tananbaum, as managing member of the respective management entities, may be deemed to have sole voting and dispositive power over the shares. The ownership percentages are based on 10,841,470 common shares outstanding as of October 9, 2026.
Quince Therapeutics, Inc. (QNCX) is identified as the issuer in a beneficial-ownership report naming Perceptive Advisors LLC, Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd. Each reports beneficial ownership of 912,853 common shares, or 8.4%, with shared voting and dispositive power. The Master Fund directly holds those shares; Perceptive Advisors manages the fund, and Edelman is Perceptive Advisors’ managing member. The percentages are based on 10,841,470 common shares expected to be outstanding following conversion of Series C Preferred Stock, as reported October 9, 2026.
The Master Fund also holds warrants exercisable for 456,427 common shares or 8,777.43 Series C Preferred Stock shares. These warrant shares are excluded from reported ownership because the triggering event has not occurred and the warrants cannot yet be exercised. Exercise is subject to a 9.99% beneficial-ownership limit and a limited exercise window following the trigger.